PBM — Psyence Biomedical Income Statement
0.000.00%
Last trade - 00:00- $0.23m
- -$0.50m
Annual income statement for Psyence Biomedical, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | fx Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 1.85 | 3.23 | 46.4 | 3.66 |
| Operating Profit | -1.85 | -3.23 | -46.4 | -3.66 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -1.85 | -3.21 | -51.2 | 1.01 |
| Net Income After Taxes | -1.85 | -3.21 | -51.2 | 1.01 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -1.85 | -3.21 | -51.2 | 1.01 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -1.85 | -3.21 | -51.2 | 1.01 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -82.6 | -143 | -335 | 41.8 |
| Dividends per Share |